Novacyt S.A. (ALNOV.PA)
- Previous Close
0.4580 - Open
0.4500 - Bid --
- Ask --
- Day's Range
0.4451 - 0.4575 - 52 Week Range
0.4185 - 1.5900 - Volume
108,467 - Avg. Volume
227,088 - Market Cap (intraday)
33.408M - Beta (5Y Monthly) -0.04
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6100 - Earnings Date Apr 30, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, France, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, and Yourgene Health segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The company was incorporated in 2006 and is based in Le Vésinet, France.
www.novacyt.comRecent News: ALNOV.PA
View MorePerformance Overview: ALNOV.PA
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALNOV.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALNOV.PA
View MoreValuation Measures
Market Cap
31.64M
Enterprise Value
8.32M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.45
Price/Book (mrq)
0.38
Enterprise Value/Revenue
0.38
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-212.72%
Return on Assets (ttm)
-10.19%
Return on Equity (ttm)
-57.28%
Revenue (ttm)
19.63M
Net Income Avi to Common (ttm)
-38.7M
Diluted EPS (ttm)
-0.6100
Balance Sheet and Cash Flow
Total Cash (mrq)
30.46M
Total Debt/Equity (mrq)
24.81%
Levered Free Cash Flow (ttm)
-17.18M